Flash Finance

Albert David LimitedALBERTDAVDCorporate

Pharmaceuticals - Indian - Bulk Drugs & Formln Latest results: Jun 2026 14 quarters of data
Consolidated Standalone
₹831.00
MCap ₹474 Cr · P/E 20.4
Albert David Limited — Stock analysis & AI research Albert David Limited — Seasonality — best & worst months Albert David Limited — Technical setup — score, trend, support & resistance Albert David Limited — Live exchange announcements
🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹101 Cr
Sales · Jun 2026
+42.3% YoY
₹11 Cr
Operating Profit · Jun 2026
+200.0% YoY
10.9%
OPM % · Jun 2026
+170.3% YoY
₹32 Cr
Net Profit · Jun 2026
+300.0% YoY
₹56.07
EPS · Jun 2026
+303.1% YoY

📝 Albert David Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Albert David Limited reported revenue of ₹101 crore for the quarter ended June 2026 (Q1 FY27), up 42.3% from ₹71 crore in the same quarter last year, and up 17.4% sequentially over the March 2026 quarter.

Net profit rose 300.0% year-on-year to ₹32 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹56.07.

Operating profit stood at ₹11 crore — an operating margin (OPM) of 10.9%, compared with -15.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Albert David Limited posted revenue of ₹334 crore, a decline of 96.4% over FY25, with a net loss of ₹1 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹364 crore with a net profit of ₹23 crore.

Valuation snapshot

At the current price of ₹831.00, ALBERTDAVD has a market capitalisation of ₹474 crore and a trailing P/E of about 20.4.

Within the Pharmaceuticals - Indian - Bulk Drugs & Formln industry, it is the 25th-largest of the 47 companies we track by market value.

Shareholding pattern

As of Sep 2026, promoters held 62.24%, foreign institutional investors (FIIs) 0.60%, domestic institutional investors (DIIs) 1.64%, public shareholders 35.53% of Albert David Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹474 Cr
Current Price ?
₹831.0
P/E ?
20.35below ind
Industry P/E ?
37.20
P/B ?
1.21
P/S ?
1.30
P/FCF ?
-13.17
Enterprise Value ?
₹504 Cr
EV/EBITDA ?
18.12
PEG ?
N/A
Earnings Yield ?
3.6%
Dividend Yield ?
0.60%
Profitability & Returns
Sales (TTM) ?
₹364 Cr
OPM ?
7.6%
Profit after tax (TTM) ?
₹23 Cr
EPS (TTM) ?
₹40.83
ROCE ?
1.0%
ROE ?
5.9%
ROA ?
4.5%
Growth
Sales — latest qtr ?
₹101 Cr
PAT — latest qtr ?
₹32 Cr
YoY qtr sales growth ?
42.3%
YoY qtr profit growth ?
300.0%
Sales growth (3y) ?
-1%
Sales growth (5y) ?
6%
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹30 Cr
Debt to Equity ?
0.08
Interest Coverage ?
-1.2
Current Ratio ?
N/A
Ownership
Promoter holding ?
62.24%
Change in promoter holding ?
0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
18.7%
Return 6 months ?
15.9%

🗓️ Quarterly results (14 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 81929388898,93698837571879086101 +42.3% +17.4%
Operating Profit 1013168108861-5-11311311 +200.0% +266.7%
Other Income 0181217102,30621-9-522-212-2528 +27.3% +212.0%
Interest 00000900011101 +0.0% —
Depreciation 2212217822222232 +0.0% -33.3%
Profit Before Tax 7292723182,20625-10-128-320-2536 +350.0% +244.0%
Net Profit 4232019131,88418-9-108-315-2132 +300.0% +252.4%
EPS 6.5441.1635.5732.8022.6233.0231.67-16.45-18.1013.91-5.7826.81-37.5556.07 +303.1% +249.3%
OPM % 12.3% 14.1% 17.2% 9.1% 11.2% 1.0% 6.3% 1.2% -6.7% -15.5% 3.4% 12.0% 3.5% 10.9% +170.3% +211.4%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹9,192 Cr ₹334 Cr ₹364 Cr -96.4%
Operating Profit ₹90 Cr ₹6 Cr ₹28 Cr -93.5%
OPM % 0.98% 1.74% 7.65% +77.6%
NPM % 20.49% -0.21% 6.40% -101.0%
Other Income ₹2,313 Cr ₹7 Cr ₹13 Cr -99.7%
Depreciation ₹184 Cr ₹9 Cr ₹9 Cr -94.9%
Interest ₹9 Cr ₹3 Cr ₹3 Cr -69.1%
EBIT ₹-94 Cr ₹-4 Cr ₹18 Cr +96.2%
PBT ₹2,209 Cr ₹-0 Cr ₹28 Cr -100.0%
Tax ₹329 Cr ₹5 Cr ₹5 Cr -98.6%
Net Profit ₹1,884 Cr ₹-1 Cr ₹23 Cr -100.0%
EPS ₹30.14 ₹-2.61 ₹39.55 -108.7%
Material Cost ₹2,871 Cr ₹31 Cr ₹31 Cr -98.9%
Employee Cost ₹2,866 Cr ₹24 Cr ₹24 Cr -99.2%
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 6666 +0.0%
Reserves 306377387386 -0.3%
Borrowings 531230 +150.0%
Other Liabilities 10611210798 -8.4%
Total Liabilities 423498511519 +1.6%
Fixed Assets 808399100 +1.0%
CWIP 37221 +950.0%
Investments 193273260243 -6.5%
Other Assets 148135151155 +2.6%
Total Assets 423498511519 +1.6%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 1146-28-8 +71.4%
Cash from Investing Activity -5-3323-4 -117.4%
Cash from Financing Activity -6-8012 —
Net Cash Flow -14-5-0 +100.0%
Free Cash Flow 635-43-36 +16.3%
CFO/OP 59%131%-629%-49% +92.2%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 32302937 +27.6%
Inventory Days 149126201187 -7.0%
Days Payable 9598118104 -11.9%
Cash Conversion Cycle 8758112120 +7.1%
Working Capital Days 14-136247 +4016.7%
ROCE % 17%28%6%1% -83.3%

👥 Shareholding (latest 6 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026 % Chg
Promoters 62.23%62.23%62.23%62.23%62.24%62.24% +0.0%
FIIs 0.84%0.60%0.60%0.58%0.57%0.60% +5.3%
DIIs 1.65%1.65%1.65%1.65%1.64%1.64% +0.0%
Public 35.27%35.50%35.51%35.52%35.56%35.53% -0.1%
No. of Shareholders 15,07014,66613,96713,55513,15512,709 -3.4%

⚖️ Peer comparison

Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln · top 25 of 47 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 AKUMS Akums Drugs ₹784.55 12,012 41.2 4,502 293 12.6% 6.5% 5.9% -25.5% 13.9% 56.1%
2 STAR Strides Pharma ₹1,085.00 10,001 26.7 3,636 389 25.4% 10.7% -20.4% 99.0% 11.2% 50.0%
3 BLUEJET Blue Jet ₹565.05 9,802 36.9 884 265 36.3% 30.0% 8.0% 0.7% -17.5% -14.3%
4 AARTIPHARM Aarti Pharmalabs ₹828.30 7,511 36.1 1,957 208 22.0% 10.6% 1.5% -26.9% 42.4% 39.2%
5 SUPRIYA Supriya Lifescience ₹870.30 7,004 35.3 873 198 33.2% 22.7% 18.9% 11.1% 30.8% -30.9%
6 INNOVACAP Innova Captab ₹1,199.30 6,863 13.8 5,779 497 14.6% 8.6% 355.1% 277.4% 33.9% 42.3%
7 MOREPENLAB Morepen Laboratories ₹123.35 6,759 48.0 1,951 141 9.4% 7.2% -0.3% -18.3% 34.1% 394.0%
8 IOLCP IOL Chemicals ₹201.19 5,905 35.2 2,523 168 12.3% 6.7% 11.5% 36.6% 37.1% 89.8%
9 FDC FDC ₹350.20 5,702 19.5 2,191 291 15.3% 13.3% 3.0% 4.8% 3.0% 9.5%
10 NOVARTIND Novartis India ₹2,257.80 5,575 57.0 371 97 27.6% 26.2% -0.3% -6.9% 18.2% 14.3%
11 ORCHPHARMA Orchid Pharma ₹1,058.75 5,370 236.9 812 22 5.1% 2.7% -11.9% -76.4% 0.2% 25.4%
12 RPGLIFE RPG Life ₹2,865.90 4,740 39.7 735 120 21.1% 16.3% 8.4% -36.9% 15.8% 16.3%
13 ZOTA Zota Health ₹1,232.70 4,269 — 609 -104 0.6% -17.1% 84.6% -29.8% 66.9% -213.9%
14 GUFICBIO Gufic Biosciences ₹419.85 4,210 57.3 974 74 16.9% 7.6% 14.7% -9.1% 14.9% 86.0%
15 UNICHEMLAB Unichem Laboratories ₹526.70 3,708 12.2 2,308 305 9.9% 13.2% 6.2% 74.1% 20.1% 496.1%
16 INDSWFTLAB Ind-Swift Laboratories ₹374.00 3,252 55.4 665 57 9.0% 8.6% 235.3% 10.1% 32.3% -88.7%
17 ADVENZYMES Advanced Enzyme ₹293.25 3,249 19.8 750 172 29.8% 22.9% 17.1% 29.6% 2.1% -4.6%
18 SOLARA Solara Active ₹667.00 3,218 85.6 1,535 37 15.2% 2.4% 6.6% -1470.4% 33.1% 381.8%
19 DCAL Dishman Carbogen ₹162.08 2,541 157.6 2,902 16 16.7% 0.6% 8.1% 2655.7% -4.3% -351.7%
20 INDOCO Indoco Remedies ₹254.59 2,347 n/m 1,872 3 8.8% 0.2% 10.7% -26.5% 6.5% 280.0%
21 PANACEABIO Panacea Biotec ₹368.55 2,257 — 673 -9 0.3% -1.3% 14.4% 17.9% 19.7% -44.4%
22 REMUS Remus Pharma. ₹1,911.30 2,252 91.1 94 25 31.7% 26.7% — — 13.3% 21.4%
23 SAKAR Sakar Healthcare ₹987.40 2,167 61.0 272 36 28.5% 13.3% 41.9% 71.8% 38.4% 120.2%
24 JAGSNPHARM Jagsonpal Pharmaceuticals ₹227.53 1,501 33.3 294 45 20.7% 15.4% 6.9% -22.2% 8.5% 20.4%
25 ALBERTDAVD Albert David ₹845.50 483 21.4 364 23 7.6% 6.4% -96.4% -100.0% 42.3% 300.0%
❓ Frequently asked questions
What was Albert David Limited's revenue in Q1 FY27?
Albert David Limited reported revenue of ₹101 crore for the quarter ended June 2026 (Q1 FY27), up 42.3% from ₹71 crore in the same quarter last year, and up 17.4% sequentially over the March 2026 quarter.
What was Albert David Limited's net profit in Q1 FY27?
Net profit rose 300.0% year-on-year to ₹32 crore, from ₹8 crore. Earnings per share (EPS) came in at ₹56.07.
What is ALBERTDAVD's market capitalisation and P/E ratio?
At the current price of ₹831.00, ALBERTDAVD has a market capitalisation of ₹474 crore and a trailing P/E of about 20.4.
Who owns Albert David Limited? (shareholding pattern)
As of Sep 2026, promoters held 62.24%, foreign institutional investors (FIIs) 0.60%, domestic institutional investors (DIIs) 1.64%, public shareholders 35.53% of Albert David Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI